Author Archives: Marisa Wexler

Nanoparticles as transport agents have a potential to more effectively deliver medications to the brain, opening neurological disorders such as Parkinson’s disease to new treatments, a study suggested. But work is needed to further refine these particles, assuring their safety as well as their efficacy, its researchers wrote. The study,…

Most people with Parkinson’s disease have positive attitudes about telemedicine during the COVID-19 pandemic, a small Japanese study reveals. The study, “Attitudes towards telemedicine of patients with Parkinson’s disease during the COVID‐19 pandemic,” was published in Neurology and Clinical Neuroscience. It was funded by…

A new wearable device could enable monitoring of motor symptoms as well as electrical activity of the brain, heart, and muscles in people with Parkinson’s disease. The device was described in the journal Sensors, in the study “A Multi-Sensor Wearable System for the Quantitative Assessment of…

People with young onset Parkinson’s disease have unique features that should be taken into account when providing care and conducting research, a recent review article highlights. The paper, “Young Onset Parkinson’s Disease: A Modern and Tailored Approach,” was published in the Journal of Parkinson’s Disease. Parkinson’s usually…

Starting treatment earlier does not appear to worsen the course of Parkinson’s disease or be associated with more severe treatment side effects, an observational study reports. The study, “Estimating the Effect of Early Treatment Initiation in Parkinson’s Disease Using Observational Data,” was published in the journal…

People who are infected with SARS-CoV2 — the virus that causes COVID-19 — may be at greater risk of later developing Parkinson’s disease, researchers suggest in a commentary. In their commentary, “Is COVID-19 a perfect storm for Parkinson’s disease?” published in  Trends in Neurosciences,…

The U.S. Food and Drug Administration (FDA) has named  Cala Trio a breakthrough device as a potential wrist-worn treatment of action tremors in the hands of adults with Parkinson’s disease. This designation is given to medical devices with the potential to more effectively treat diseases that are life-threatening or irreversibly debilitating. It…

Sanofi will provide $1 million in research funding over the next two years to support PD GENEration, a national initiative seeking to increase the availability of genetic testing and counseling for people with Parkinson’s disease living in the U.S. “Genetic testing is critical for advancing…

Rodent neurons (nerve cells) in cell cultures form complex interaction networks that seem designed to maximize information processing, but are distinct from many well-understood mathematical models, new research suggests. Understanding how these networks form and interact within the brain could have applications in understanding neurological diseases like Parkinson’s and…

Targeting certain regions of the alpha-synuclein protein could be a viable therapeutic strategy for Parkinson’s disease, a study suggests. The study, “Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein,” was published in the journal Molecular Neurodegeneration. Parkinson’s disease is characterized by…